Thank you for Subscribing to Life Science Review Weekly Brief
Fremont, CA: 2021 has been a disruptive year for the life sciences industry. While the COVID-19 pandemic disrupted thousands of clinical trials across the globe, the life sciences industry rose to the occasion and accelerated vaccine trials. Not only that, giants in this industry embraced advanced technologies in order to boost innovation.
PharmAbcine, a clinical-stage biotech company, is known for its relentless effort in the development of fully human antibody therapeutics. The company's Chairman and Chief Executive Officer, Dr. Jin-San Yoo, has been invited to participate in the 40th Annual J.P. Morgan Healthcare Conference over January 10-13, 2022. The company also plans to present at Biotech Showcase 2022 during the J.P. Morgan Week.
Details of the events are as follows:
Event: J.P. Morgan Healthcare Conference (BIO @ JPM) 2022
Date: January 10-13, 2022
Event: Biotech Showcase 2022
Date: January 10-12, 2022 (in-person, San Francisco, U.S)
January 17-19, 2022 (Virtually)
Dr. Yoo and the company's business development team are expected to attend these events and hold virtual one-on-one meetings with registered investors and pharmaceutical companies to launch PharmAbcine's business and explore potential investment, licensing deals, and co-development opportunities for the main pipelines.
The main pipelines of the company include olinvacimab, PMC-403, and PMC-309.
Olinvacimab, a fully human anti-VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) antibody, is the company's lead pipeline candidate, with multiple global clinical trials underway.
PharmAbcine received HREC (Human Research Ethics Committees) approval in early September 2021 for a Phase II olinvacimab and pembrolizumab combo study for the treatment of mTNBC (metastatic Triple-Negative Breast Cancer) in Australia. A Phase II olinvacimab mono study for bevacizumab-nonresponding rGBM (recurrent glioblastoma multiforme) patients at multiple sites in both the US and Australia is also ongoing.
As are two Phase Ib olinvacimab and pembrolizumab combo trials in mTNBC and rGBM in Australia.
PMC-403 is a fully human Tie2-activating antibody that has been designed to stabilize and repair damaged blood vessels in a variety of indications. PMC-403 is currently being developed for the treatment of neovascular ophthalmology indications such as AMD (Age-related Macular Degeneration), DR (Diabetic Retinopathy), and DME (Diabetic Macular Edema) (Diabetic Macular Edema). PMC-403 GLP-Tox studies are currently underway to assess the safety profile, and the company anticipates that global clinical trials will begin in 2022.
PMC-309 is a novel anti-VISTA (V-domain Ig Suppressor of T cell Activation) antagonizing antibody developed to treat various cancers. The immune checkpoint receptor VISTA, which is primarily expressed on MDSC (Myeloid-Derived Suppressor Cells) and Tregs (regulatory T cells), is known to play a critical role in maintaining the immunosuppressive environment around tumor cells. Nonclinical studies have revealed that PMC-309 inhibits VISTA pathways, induces T cell activation, and leads to improved anti-tumor effects. PMC-309 is also being studied for GLP-Tox, and it will begin a global clinical trial in 2022.
"Pharma organizations from all over the world have already begun placing their bets on combination therapies using PharmAbcine’s drug candidates to achieve successful outcomes for cancer treatment," added Dr. Jin-San Yoo.
PharmAbcine has been selected as one of the Top Biotech Companies in APAC 2021 by the Life Sciences Review magazine.